| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c23490b29dab5ca4c6f5c84cc795b11 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-606
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-604
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-603
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-602
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-1307
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0606
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0648
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70539
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0696 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0735 |
| filingDate |
2021-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e48b8720c473011f4187057f63394083
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_047f1f3e20044c601b3c1916898ce125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96b9fcdc16d022e68f037444e6c38580 |
| publicationDate |
2021-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20210095586-A |
| titleOfInvention |
Off-the-shelf stem cell and immune cell, and a pharmaceutical composition |
| abstract |
The present invention relates to a totipotent stem cell in which the expression of a beta-2 microglobulin (B2M) gene is suppressed and an immune rejection response is suppressed by expression of a cluster of differentiation 24 (CD24) gene, and a pharmaceutical composition comprising the same will be. |
| priorityDate |
2020-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |